# **International Journal of Internal and Emergency Medicine**

9

# Increased Risk for Ischemic Stroke of Non-Cardioembolic Origin in Italian Patients Carrying the Haptoglobin 2-2 Phenotype

Antonio Ponzetto<sup>1\*</sup>, Giulia Fiorini<sup>2</sup>, Emanuela Morra<sup>1</sup> and Alberto Marchet<sup>3</sup>

<sup>1</sup>Department of Medical Sciences, University of Turin, Italy <sup>2</sup>Department of Medical and Surgical Sciences, University of Bologna, Italy <sup>3</sup>Department of Stroke, Hospital Martini, Italy

## Abstract

Free iron is toxic to cells and total body iron stores are linked to the risk of developing atherosclerosis and stroke. Haptoglobin, a physiological scavenger of hemoglobin, prevents free iron spillage into cells; however, the haptoglobin 2-2 phenotype is poorly capable of binding hemoglobin. We hypothesized that the risk of stroke may be influenced by haptoglobin phenotypes and we investigated this hypothesis on a series of patients with acute ischemic stroke of non-cardioembolic origin.

**Cases:** A 160 patients were admitted to the stroke units of two Turin hospitals due to an episode of acute ischemic stroke of non-cardioembolic origin; there were two blood donor controls for each patient.

Methods: Immunoblotting was used to detect the haptoglobin phenotype.

**Results:** The haptoglobin 2-2 phenotype was significantly more frequent in the stroke patients compared to the controls (69% versus 45%, respectively; p =0.003) (Figure 1).

# **OPEN ACCESS**

#### \*Correspondence:

Antonio Ponzetto, Department of Medical Sciences, University of Turin, Corso AM Dogliotti 14, 10126 Torino, Italy, Tel: 39 011 6708483 Fax: 390116334515; E-mail: antonio.ponzetto@unito.it Received Date: 26 Mar 2018 Accepted Date: 14 May 2018 Published Date: 16 May 2018

#### Citation:

Ponzetto A, Fiorini G, Morra E, Marchet A. Increased Risk for Ischemic Stroke of Non-Cardioembolic Origin in Italian Patients Carrying the Haptoglobin 2-2 Phenotype. Int J Intern Emerg Med. 2018; 1(1): 1005.

Copyright © 2018 Antonio Ponzetto. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. **Conclusions:** The haptoglobin 2-2 phenotype appears to be a novel risk factor for ischemic stroke of non-cardioembolic origin in Italian patients.

Keywords: Ischemic Stroke; Haptoglobin; Iron; Free iron; Total body iron

## Introduction

Stroke was ranked second cause of death after ischemic heart disease worldwide up to 2010 and third in the USA [1,2]. Ischemic Stroke (IS) doubled among people aged 18 years to 64 years so that presently it is the primary cause of long-term disability in the USA [3]. While all age groups are at risk, the highest incidence is observed in older ages with no predilection for sex [3-5]. The mortality from IS is constantly descending [3]; among those who suffered first episode at age less than 50 years, cumulative mortality risks were 2.7% after first month, 4.7% and 10.7% at 1year and 5 years respectively [6] (Table 1). Nonetheless, 68% of stroke survivors rely on external help for coping with day-to-day life. Long-term care dominates the lifetime costs for stroke patients, with an average cost of care per person per year of 30,700 Euros in Italy [7]. Given the inevitable rise in medical costs for stroke patients owing to longer life expectancies and an aging world population, prevention is the most effective means to diminish the personal, economic, and social burden.

Epidemiological studies have identified non-modifiable risk factors: age and gender, hereditary predisposition and race. Stroke incidence reportedly doubles every 8 years of age and is more prevalent among male patients aged 65 years or over [8]. In the USA, African-Americans, Asians and Hispanics have a higher rate of stroke, whilst in Europe, the highest incidence is observed in Russia and Eastern European countries [9,10].

Modifiable risk factors for stroke are hypertension, atherosclerosis, previous cardiovascular diseases and Transient Ischemic Attack (TIA) [11-14]. Effective control of blood pressure was found to diminish stroke rates by 33% to 50% compared with unsuccessfully-treated hypertensive patients [15]. Taken together, the classic risk factors account for 50% of strokes. Body iron stores have been reported as a risk factor for developing carotid atherosclerosis [16]; serum levels of ferritin are one

Table 1: Haptoglobin haplotype frequency distribution in 320 controls and 160 patients with ischemic stroke.

| Haptoglobin haplotypes                          | Controls N=320 (%) | Patients N=160 (%) | χ2                |
|---|--------------------|--------------------|-------------------|
| Hp 1-1  | 44 / 320 (13.75)   | 18 / 160 (11.25)   | NS                |
| Hp 2-1  | 136 / 320 (42.50)  | 44 / 160 (27.50)   | χ²=4436; p=0.03   |
| Нр 2-2  | 140 / 320 (43.75)  | 98 / 160 (61.25%)  | χ²=3918; p=0.04   |
| Haptoglobin haplotypes (Hp 1-1, Hp 2-1, Hp 2-2) | controls (320)     | patients (160)     | χ²=13504; p=0.005 |

The  $\chi 2$  test was used to calculate the statistical difference.

Table 2: Baseline Characteristics of the stroke patients and controls.

|                 | Number | Mean Age (years) | Hypertension     | Obesity         | Smokers          |
|-----------------|--------|------------------|------------------|-----------------|------------------|
| Controls Male   | 168    | 51±20            | 23.81% (40/168)  | 17.86% (30/168) | 39.88% (67/168)  |
| Controls Female | 152    | 42±19            | 19.74% (30/152)  | 18.42% (28/152) | 33.55% (51/152)  |
| Patients Male   | 120    | 53±20            | 83.33% (100/120) | 51.67% (62/120) | 89.16% (107/120) |
| Patients Female | 40     | 51±20            | 25% (10/40)      | 12.5% (5/40)    | 12.5% (5/40)     |

Results are shown as means ±SD.

of the strongest indicators of carotid artery diseases in both sexes, especially in persons under 60 years of age [16]. Lipid peroxidation is considered the major pathogenic factor for developing carotid atherosclerosis because of its possible link with concentrations of tissue iron, one of the strongest oxidants in vivo [17-19]. Free iron is toxic for cells, particularly for those in the Central Nervous System (CNS) [20,21]. Iron-induced atherosclerosis resulted from the Kuopio Ischemic Heart Disease study, Kiechl, and Van der A. [22,19]. In postmenopausal women; the latter group found serum ferritin to be a risk factor for stroke in these patients [23]. The evidence shows that iron may cause lipid peroxidation, which directly induces Oxidation of Low Density Lipoproteins (ox-LDL), a major mechanism for atherogenesis [24,25]. The total amount of body iron stores and of free circulating iron in particular, depends on genetic traits, including Haptoglobin (Hp) levels. The Hp 2-2 phenotype is far less able to bind Hemoglobin (Hb), resulting in free iron being available [26]. Hp is a plasma protein responsible for the removal of free Hb from the circulation [27]. After hemolysis, stable Hp-Hb complexes are delivered to the hepatic parenchymal cells by receptor-mediated endocytosis [28,29]. Hp is characterized by a genetic polymorphism with three structurally different phenotypes (Hp 1-1, Hp 2-1 and Hp 2-2), Hp 1-1 is a small molecule (86 kDa) of well-defined structure, whereas Hp 2-1 is characterized by heteropolymers (86 kDa to 300 kDa), and Hp 2-2 forms large macromolecular complexes (170 kDa to1000 kDa) [26]. The hemoglobin binding capacity depends on the genetic Hp type, the amount of Hp, and the number of polymers [30,31]. Hp type 1-1 has the greatest hemoglobin-binding capacity, while type 2-2 is almost unable to carry Hb as the Hb binding sites are occupied due to the polymerization process [32].

Individuals bearing the Hp 2-2 phenotype are more likely to develop essential and refractory hypertension, Obstructive Sleep Apnea Syndrome (OSAS), and peripheral arterial occlusive disease [33-35].

We decided to investigate whether the Hp phenotype could also be involved in the pathogenesis or severity of non-cardioembolic IS.

#### **Materials and Methods**

#### Patients and controls

The patient group consisted of 160 subjects (120 males and 40 females, mean age  $52 \pm 20$  years old) admitted to the Stroke Units of the Ospedale Martini and the Ospedale San Giovanni Battista (Molinette), Torino, in one year.



controls and 160 patients with ischemic stroke.  $\chi^2 = 13504$ ; p =0.005

Diagnosis of ischemic stroke was based on the criteria of the World Health Organization Report of the WHO Task Force on stroke and other cerebrovascular disorders [36]. All patients underwent diagnostic imaging for CNS and cardiac pathologies, including Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI) scans, duplex ultrasound for carotid artery diseases and transthoracic echocardiography.

Exclusion criteria were: previous or present cardiac arrhythmias; known blood clotting abnormalities; cancer with or without radiation therapy to the head and neck region. A further exclusion criterion was being of non-Italian descent, but no such individual presented to either stroke unit for acute stroke of non-cardioembolic origin during the study period.

The control group consisted of 320 blood donors (168 males and 152 females, mean age 46  $\pm$  20 years) referred from the Blood Bank of the San Giovanni Battista Hospital. Cases and controls resided in Turin, Northwestern Italy (Table 2, 3).

#### Haptoglobin determination

Blood samples from patients were collected, immediately centrifuged, and serum was stored at -70°C. A volume of 5  $\mu$ l of plasma diluted in saline solution at 1:50 was mixed with 2  $\mu$ l of 1 M phosphate buffer pH 7.0 and 10  $\mu$ l of 9 M urea, and immediately frozen at -70°C for 2 hours. Before electrophoresis, samples were mixed with bromophenol blue and 10  $\mu$ l of × 5 sample buffer (10% SDS and 2.5 mL 0.5 M TRIS-HCl, pH 6.8 and 2 mL glycerol), then boiled for 5 min [37]. Samples were run on an 8% acrylamide/bisacrylamide gel (30% w/v GIBCO Life Technologies, Gaithersburg,

| Markers             | Controls N =320 (%) | Patients N =160 (%) | P value |
|---------------------|---------------------|---------------------|---------|
| Smokers             | 118 (36.38)         | 112 (70)            | 0.01    |
| High blood pressure | 70 (21.87)          | 110 (68.75)         | <0.001  |
| Obesity             | 58 (18.13)          | 67 (41.87)          | 0.015   |

 Table 3: Risk factor analysis in 320 controls and 160 patients with ischemic stroke.

 Table 4: Analysis of four blood markers in 320 controls and 160 patients with ischemic stroke.

| Markers             | Controls N =320    | Patients N =160    | P value |
|---------------------|--------------------|--------------------|---------|
| Blood glucose level | 85 ± 16 mg/dL      | 124 ± 33 mg/dL     | <0.003  |
| Total cholesterol   | 179.0 ± 36.1 mg/dL | 236.7 ± 68.7 mg/dL | <0.05   |
| White blood cells   | 7.23 ± 3.63 K/µL   | 8.5 ± 4.39 K/µL    | NS      |
| Hemoglobin          | 12.67 ± 2.30 g/dL  | 16.9 ± 1.0 g/dL    | 0.05    |

Plus-minus values are means ± SD

MD, USA) using the buffer system of Laemmli for 45 minutes at 200 volts, then transferred onto a nitrocellulose membrane (Hybond ECL, Amersham, Cleveland, OH, USA) for 80 minutes at 50 volts, according to the Western blotting procedure [38-40]. After overnight saturation in 10% PBS-BSA (phosphate buffered salinebovine serum albumin), membranes were washed with PBS-Tween 0.1% and incubated with the primary antibody (mouse anti-human haptoglobin Abs, Sigma-Aldrich, Milan, Italy), at a dilution of 1:4000 (in PBS-Tween), for 90 minutes. Before exposure to a 1:1000 PBS-Tween dilution of peroxidase-conjugated anti-mouse IgG from sheep (Amersham), membrane strips were washed for 30 minutes with four changes of PBS-Tween buffer. The Hp bands were visualized with a chemiluminescence method using ECL reagents (Amersham). The maximum light emission was 428 nm detected by a short exposure to blue-light sensitive autoradiography film (Hyperfilm ECL, Amersham). Protein concentrations were determined with BCA reagents (Pierce, Rockford, IL, USA) using BSA as the standard.

#### Laboratory blood chemistry

Standard laboratory methods were used to measure serum concentration of glucose, total cholesterol, white blood cells and hemoglobin.

#### Statistical analysis

Data are reported as means  $\pm$  Standard Deviation (SD). The distribution of the Hp phenotype in cases and controls were compared using the chi-square test ( $\chi^2$ ) (Table 4).

#### Results

#### Hp phenotype frequency

The incidence of Hp 2-2 was 61.25% in the ischemic stroke group and 43.75% in the control group (p =0.04) ( $\chi^2$  =3918); the incidence of Hp 1-1 and 2-1 in the ischemic stroke group was 11.25% and 27.50%, respectively, and 13.75% and 42.50%, respectively, in the control group (Table 1). The higher frequency of the Hp 2-2 phenotype in patients with acute ischemic stroke suggests that it may genetically favor cardiovascular diseases (Table 1).

#### Discussion

This study report- for the first time in an Italian population- a correlation between the Hp 2-2 phenotype and susceptibility to acute ischemic stroke of non-cardioembolic origin. The increased frequency of the Hp 2-2 phenotype in stroke patients suggests that this genetic trait may represent a marker for increased susceptibility to ischemic

stroke of non-cardioembolic origin. The  $\chi^2$  test showed a significant difference (p =0.04) between Hp 2-2 phenotype distributions in patients and controls ( $\chi^2$  =3918). In a study on different European populations, the reported distribution of Hp phenotypes 1-1, 2-1 and 2-2 was 16%, 48%, and 36%, respectively [41]. The distribution in our controls was slightly different: 13.75%, 42.50%, and 43.75%, respectively. This discrepancy in phenotype distribution weakened the support for the apparent association between the Hp 2-2 phenotype and susceptibility for ischemic stroke.

A highly significant increase in the incidence of the Hp 2-2 phenotype was reported for a group of patients at high risk for myocardial infarction compared to a control group [42]. Ijäs et al just reported a 2.4 higher risk of dying due to cardiovascular disease for patients carrying the Hp2 allele, after their first ischemic stroke [43].

The Hp 2-2 phenotype appears to be a genetic risk factor for developing coronary atherosclerosis and peripheral arterial occlusive disease. A higher susceptibility to cardiovascular disease in OSAS was also correlated with the Hp 2-2 phenotype.

The median age of the population of Turin was 46.1 years in 2016 much higher than that of the general population in the USA (37.9 years in 2015) [44]. Since the ageing Turin population is at increased risk of IS, methods that can ascertain risk factors for it are important.

Around 40% of Italians aged 35 years to 64 years have high blood pressure; in this age group, the mortality rate for ischemic stroke is 40 in 100,000 people [45]. This means that approximately 1 in 1000 deaths at age 35 years to 64 years are stroke-related [45]. It is therefore essential that stroke-preventive programs target highrisk individuals. Risk factor analysis (Table 3) suggests that elevated triglyceride levels and hypercholesterolemia are seldom relevant in the pathogenesis of ischemic stroke [46]. We therefore propose a method for identifying people at risk of ischemic stroke, namely those with an Hp 2-2 phenotype, alongside hypertension and other known risk factors. Further work is needed to determine whether a more aggressive treatment can benefit those patients with an increased risk of stroke.

#### Acknowledgments

This study was supported by an unrestricted grant to AP from Rotfil SpA. (Torino, Italy).

# **References**

- Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245-54.
- Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
- Krishnamurthi RV, Moran AE, Feigin VL, Barker-Collo S, Norrving B, Mensah GA, et al. Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Adults Aged 20-64 Years in 1990-2013: Data from the Global Burden of Disease 2013 Study. Neuroepidemiology. 2015;45(3):190-202.
- Khaw KT, Barrett-Connor E, Suarez L, Criqui MH. Predictors of strokeassociated mortality in the elderly. Stroke. 1984;15(2):244-8.
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
- 6. Putaala J, Curtze S, Hiltunen S, Tolppanen H, Kaste M, Tatlisumak T, et

al. Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke. 2009;40(8):2698-703.

- Fattore G, Torbica A, Susi A, Giovanni A, Benelli G, Gozzo M, et al. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study. BMC Neurology. 2012;12(1):137.
- 8. Health Technology Assessment 2003; 7 Nº 31:3.
- Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CD. Ethnic differences in incidence of stroke: prospective study with stroke register. Bmj. 1999;318(7189):967-71.
- Rastenyte D, Cepaitis Z, Sarti C, Bluzhas J, Tuomilehto J. Epidemiology of stroke in Kaunas, Lithuania. First results from the Kaunas Stroke Register. Stroke. 1995;26(2):240-4.
- 11. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765-74.
- 12. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet.1990;335(8693):827-38.
- Dyken ML. American Heart Association Prevention Conference. IV: Prevention and Rehabilitation of Stroke. Risk factors. Stroke.1997;28(7):1498-500.
- 14. Ionita CC, Andrew R. Xavier, Jawad F. Kirmani, Subasini Dash, Afshin A. Divani, Adnan I. Qureshi, et al. What proportion of stroke is not explained by classic risk factors? Preventive Cardiology. 2005;8(1):41-6.
- 15. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke. 1991;22(3):312-8.
- 16. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, et al. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arterioscler Thromb. 1994;14(10):1625-30.
- 17. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344(8925):793-5.
- Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Journal of Lipid Research. 2004;45(6):993-1007.
- 19. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96(10):3300-7.
- 20. Thompson KJ, Shoham S, Connor JR. Iron and neurodegenerative disorders. Brain Research Bulletin. 2001; 55(2):155-64.
- 21. Pless M, Lipton SA. Iron deficiency in children. N Engl J Med.1993;329(23)1741-2.
- 22. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803-11.
- 23. van der A DL, Grobbee DE, Roest M, Marx JJ, Voorbij HA, van der Schouw YT, et al. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2005;36(8):1637-41.
- 24. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339(8798):883-7.
- 25. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF, DCCT/ EDIC Research Group. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies

and human oxLDL. Clin Immunol. 2002;105(1):81-92.

- 26. Langlois MR, Martin ME, Boelaert JR, Beaumont C, Taes YE, De Buyzere ML, et al. The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clinical Chemistry. 2000;46(10):1619-25.
- Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry. 1996;42(10):1589-600.
- Kino K, Tsunoo H, Higa Y, Takami M, Hamaguchi H, Nakajima H, et al. Hemoglobin-haptoglobin receptor in rat plasma membrane. J Biological Chemistry. 1980;255(20):9616-20.
- 29. Okuda M, Tokunaga R, Taketani S. Expression of haptoglobin receptors in human hepatoma cells. Biochim Biophys Acta. 1992;1136(2):143-9.
- 30. Delanghe JR, Langlois MR, Boelaert JR, Van Acker J, Van Wanzeele F, van der Groen G, et al. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS. 1998;12(9):1027-32.
- Langlois M, Delanghe J, Boelaert J. Haptoglobin polymorphism, a genetic marker of oxidative stress in HIV-infection. InInternational Conference on HIV and Iron, Brugge, Belgium. 1997;14-15.
- 32. Prabha SP, Padma T, Ramaswamy M. Haptoglobin patterns in essential hypertension and associated conditions increase risk for Hp (2-2). Hum Hered. 1987;37(6):345-8.
- 33. Delanghe JR, Duprez DA, De Buyzere ML, Bergez BM, Claeys LR, Leroux-Roels GG, et al. Refractory hypertension is associated with the haptoglobin 2-2 phenotype. Journal of Cardiovascular Risk. 1995;2(2):131-6.
- 34. Lavie L, Lotan R, Hochberg I, Herer P, Lavie P, Levy AP, et al. Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. Sleep. 2003;26(5):592-5.
- Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis. 1999;145(2):287-92.
- 36. No authors listed. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke. 1989;20(10):1407-31.
- 37. Padma T, Valli VV. ABO blood groups, intestinal alkaline phosphatase and haptoglobin types in patients with serum hepatitis. Human Heredity. 1998;38(6):367-71.
- Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1974; 227(5259):680-5.
- 39. Jayanthi M, Habibullah CM, Ishaq M, Ali H, Babu PS, Ali MM, et al. Distribution of haptoglobin phenotypes in oesophageal and gastric cancer. J Med Genetics. 1989;26(3):172-3.
- 40. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proco Natl Acad Sci USA. 1979;76(9):4350-4.
- 41. Teige B, Olaisen B, Teisberg P. Haptoglobin subtypes in Norway and a review of Hp subtypes in various populations. Hum Hered. 1992;42(2):93-106.
- 42. Gogishvili AV, Kavtaradze VG, Mamaladze GT, Arutiunova MS, Takadze GSh. Haptoglobin phenotype distribution in patients at high risk of developing myocardial infarct. Kardiologiia. 1985;25(2):55-8.
- 43. Ijäs P, Melkas S, Saksi J, Jula A, Jauhiainen M, Oksala N, et al. Haptoglobin Hp2 Variant Promotes Premature Cardiovascular Death in Stroke Survivors. Stroke. 2017;48(6):1463-9.
- 44. http://www.tuttitalia.it/piemonte/72-torino/statistiche/indicidemografici-struttura-popolazione/accessed july20th 2017.
- 45. http://www.worldometers.info/world-population/us-population/

46. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European

countries, Canada, and the United States. J Am Med Association. 2003;289(18):2363-9.